Prognostic Mutational Signatures of NSCLC Patients treated with chemotherapy, immunotherapy and chemoimmunotherapy

Different types of therapy are currently being used to treat non-small cell lung cancer (NSCLC) depending on the stage of tumor and the presence of potentially druggable mutations. However, few biomarkers are available to guide clinicians in selecting the most effective therapy for all patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Margaret R., Wang, Yuezhu, D’Agostino, Ralph, Liu, Yin, Ruiz, Jimmy, Lycan, Thomas, Oliver, George, Miller, Lance D., Topaloglu, Umit, Pinkney, Jireh, Abdulhaleem, Mohammed N., Chan, Michael D., Farris, Michael, Su, Jing, Mileham, Kathryn F., Xing, Fei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042886/
https://www.ncbi.nlm.nih.gov/pubmed/36973365
http://dx.doi.org/10.1038/s41698-023-00373-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10042886/
https://www.ncbi.nlm.nih.gov/pubmed/36973365
http://dx.doi.org/10.1038/s41698-023-00373-0

Ejemplares similares